| 37.64 Real-Time Quote |  +0.73 / +1.98%Today’s Change | 3.30 Today|||52-Week Range 45.00 | +45.89% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $1.2B |
Company Description
Sarepta Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Its technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. The company's technology platform includes clinical trials for genetic diseases, infectious diseases and earlier programs in H1N1 influenza and other early discovery targets. It is primarily focused on rapidly advancing the development of potentially disease-modifying Duchenne muscular dystrophy drug candidates with the intent to realize the product opportunities of such candidates and provide significant clinical benefits. The company was founded on July 22, 1980 and is headquartered in Bothell, WA.
Employees
Shareholders
| Other institutional | 51.05% |
| Mutual fund holders | 18.26% |
| Individual stakeholders | 0.67% |
Top Executives
| Christopher Nishan Garabedian | President, Chief Executive Officer & Director |
| Sandesh Mahatme | Chief Financial Officer & Senior Vice President |
| Patrick L. Iversen, PhD | Senior Vice President-Research & Innovation |
| Edward M. Kaye, MD | Chief Medical Officer & Senior Vice President |
| David Ty Howton, Jr. | Senior Vice President & General Counsel |
.
